Progress in the treatment of HIV infection: Based on data presented at the XVIII International AIDS Conference (July 18-23, 2010, Vienna)

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The International AIDS Conference continues to be a forum for the dissemination of important and relevant scientific information on the treatment and management of HIV infection. The most important information from AIDS 2010 was the results of the microbicide CAPRISA 004 trial. After years of negative results, we finally have the proof that impacting the transmission of HIV through a woman-controlled, biomedical intervention is possible. This is huge progress and further developments in microbicides, as well as preexposure prophylaxis, are eagerly awaited. The antiretroviral development pipeline does not appear to be as robust as in recent years. However, it seems very likely that clinicians will have available another one-pill, once-daily treatment option in the near future with continued development of rilpivirine. Several reports from this conference highlight our continued attempts to refine HIV treatment strategies. While the results are mostly preliminary, mixed and not ready for immediate clinical application, treatment options for those who could not tolerate a certain class of antiretroviral drugs have certainly expanded and one can expect further paradigm shifts in the future in the composition of antiretroviral treatment regimens.

Original languageEnglish (US)
Pages (from-to)965-970
Number of pages6
JournalDrugs of the Future
Volume35
Issue number11
DOIs
StatePublished - Nov 2010

Fingerprint

HIV Infections
Acquired Immunodeficiency Syndrome
Rilpivirine
Anti-Infective Agents
HIV
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

@article{5ceb528cf4e1437bb33961a1fe5db998,
title = "Progress in the treatment of HIV infection: Based on data presented at the XVIII International AIDS Conference (July 18-23, 2010, Vienna)",
abstract = "The International AIDS Conference continues to be a forum for the dissemination of important and relevant scientific information on the treatment and management of HIV infection. The most important information from AIDS 2010 was the results of the microbicide CAPRISA 004 trial. After years of negative results, we finally have the proof that impacting the transmission of HIV through a woman-controlled, biomedical intervention is possible. This is huge progress and further developments in microbicides, as well as preexposure prophylaxis, are eagerly awaited. The antiretroviral development pipeline does not appear to be as robust as in recent years. However, it seems very likely that clinicians will have available another one-pill, once-daily treatment option in the near future with continued development of rilpivirine. Several reports from this conference highlight our continued attempts to refine HIV treatment strategies. While the results are mostly preliminary, mixed and not ready for immediate clinical application, treatment options for those who could not tolerate a certain class of antiretroviral drugs have certainly expanded and one can expect further paradigm shifts in the future in the composition of antiretroviral treatment regimens.",
author = "Zelalem Temesgen",
year = "2010",
month = "11",
doi = "10.1358/dof.2010.35.11.1549027",
language = "English (US)",
volume = "35",
pages = "965--970",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "11",

}

TY - JOUR

T1 - Progress in the treatment of HIV infection

T2 - Based on data presented at the XVIII International AIDS Conference (July 18-23, 2010, Vienna)

AU - Temesgen, Zelalem

PY - 2010/11

Y1 - 2010/11

N2 - The International AIDS Conference continues to be a forum for the dissemination of important and relevant scientific information on the treatment and management of HIV infection. The most important information from AIDS 2010 was the results of the microbicide CAPRISA 004 trial. After years of negative results, we finally have the proof that impacting the transmission of HIV through a woman-controlled, biomedical intervention is possible. This is huge progress and further developments in microbicides, as well as preexposure prophylaxis, are eagerly awaited. The antiretroviral development pipeline does not appear to be as robust as in recent years. However, it seems very likely that clinicians will have available another one-pill, once-daily treatment option in the near future with continued development of rilpivirine. Several reports from this conference highlight our continued attempts to refine HIV treatment strategies. While the results are mostly preliminary, mixed and not ready for immediate clinical application, treatment options for those who could not tolerate a certain class of antiretroviral drugs have certainly expanded and one can expect further paradigm shifts in the future in the composition of antiretroviral treatment regimens.

AB - The International AIDS Conference continues to be a forum for the dissemination of important and relevant scientific information on the treatment and management of HIV infection. The most important information from AIDS 2010 was the results of the microbicide CAPRISA 004 trial. After years of negative results, we finally have the proof that impacting the transmission of HIV through a woman-controlled, biomedical intervention is possible. This is huge progress and further developments in microbicides, as well as preexposure prophylaxis, are eagerly awaited. The antiretroviral development pipeline does not appear to be as robust as in recent years. However, it seems very likely that clinicians will have available another one-pill, once-daily treatment option in the near future with continued development of rilpivirine. Several reports from this conference highlight our continued attempts to refine HIV treatment strategies. While the results are mostly preliminary, mixed and not ready for immediate clinical application, treatment options for those who could not tolerate a certain class of antiretroviral drugs have certainly expanded and one can expect further paradigm shifts in the future in the composition of antiretroviral treatment regimens.

UR - http://www.scopus.com/inward/record.url?scp=79956224702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956224702&partnerID=8YFLogxK

U2 - 10.1358/dof.2010.35.11.1549027

DO - 10.1358/dof.2010.35.11.1549027

M3 - Article

AN - SCOPUS:79956224702

VL - 35

SP - 965

EP - 970

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 11

ER -